Published in J Immunol on December 01, 1998
MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med (2010) 1.95
Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. J Exp Med (2005) 1.76
Early chimerism threshold predicts sustained engraftment and NK-cell tolerance in prenatal allogeneic chimeras. Blood (2008) 1.73
Acquisition of external major histocompatibility complex class I molecules by natural killer cells expressing inhibitory Ly49 receptors. J Exp Med (2001) 1.18
The functional binding site for the C-type lectin-like natural killer cell receptor Ly49A spans three domains of its major histocompatibility complex class I ligand. J Exp Med (2001) 1.17
H-2D ligand expression by Ly49A+ natural killer (NK) cells precludes ligand uptake from environmental cells: implications for NK cell function. J Exp Med (2001) 1.15
Natural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice. PLoS One (2010) 0.96
Probing natural killer cell education by Ly49 receptor expression analysis and computational modelling in single MHC class I mice. PLoS One (2009) 0.93
Natural killer cell inhibitory receptor expression in humans and mice: a closer look. Front Immunol (2013) 0.84
Natural killer cells and their role in rheumatoid arthritis: friend or foe? ScientificWorldJournal (2012) 0.84
The balancing act: inhibitory Ly49 regulate NKG2D-mediated NK cell functions. Semin Immunol (2006) 0.81
Listeria monocytogenes infection affects a subset of Ly49-expressing NK cells in the rat. PLoS One (2010) 0.75
In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today (1990) 10.84
A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature (1998) 10.35
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 9.73
Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature (1989) 7.11
Empty MHC class I molecules come out in the cold. Nature (1990) 5.53
Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med (1985) 3.86
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70
Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice. Proc Natl Acad Sci U S A (1991) 2.68
Allorecognition by NK cells: nonself or no self? Immunol Today (1992) 2.21
Killer cells: a functional comparison between natural, immune T-cell and antibody-dependent in vitro systems. J Exp Med (1976) 2.11
Prevention of allogeneic bone marrow graft rejection by H-2 transgene in donor mice. Science (1989) 2.08
Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. J Exp Med (2000) 1.69
Recognition of autologous dendritic cells by human NK cells. Eur J Immunol (1999) 1.63
A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J Exp Med (1997) 1.59
YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J Immunol (1985) 1.51
Downregulated in adenoma gene encodes a chloride transporter defective in congenital chloride diarrhea. Am J Physiol (1999) 1.47
Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice. Nature (1980) 1.42
Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene. J Exp Med (1997) 1.38
Natural resistance against lymphoma grafts conveyed by H-2Dd transgene to C57BL mice. J Exp Med (1988) 1.34
Alteration of the natural killer repertoire in H-2 transgenic mice: specificity of rapid lymphoma cell clearance determined by the H-2 phenotype of the target. J Exp Med (1991) 1.33
Altered expression of Ly49 inhibitory receptors on natural killer cells from MHC class I-deficient mice. J Immunol (1997) 1.31
Natural NK-cell targets in the mouse thymus: characteristics of the sensitive cell population. J Immunol (1979) 1.30
The CD8+ T cell repertoire in beta 2-microglobulin-deficient mice is biased towards reactivity against self-major histocompatibility class I. J Exp Med (1994) 1.29
Restoration of H-2b expression and processing of endogenous antigens in the MHC class I pathway by fusion of a lymphoma mutant to L cells of the H-2k haplotype. Eur J Immunol (1990) 1.29
Major histocompatibility complex class I-specific and -restricted killing of beta 2-microglobulin-deficient cells by CD8+ cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1992) 1.28
Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality (1995) 1.25
Elimination of S100B and renal function after cardiac surgery. J Cardiothorac Vasc Anesth (2000) 1.24
The crystal structure of H-2Dd MHC class I complexed with the HIV-1-derived peptide P18-I10 at 2.4 A resolution: implications for T cell and NK cell recognition. Immunity (1998) 1.23
Altered phenotype and function of natural killer cells expressing the major histocompatibility complex receptor Ly-49 in mice transgenic for its ligand. Proc Natl Acad Sci U S A (1995) 1.22
NK cell-sensitive T-cell subpopulation in thymus: inverse correlation to host NK activity. Nature (1979) 1.20
Transfection of beta 2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-1 lymphoma variants. J Immunol (1990) 1.19
Human cytomegalovirus strain-dependent changes in NK cell recognition of infected fibroblasts. J Immunol (2000) 1.18
Acquisition of external major histocompatibility complex class I molecules by natural killer cells expressing inhibitory Ly49 receptors. J Exp Med (2001) 1.18
T cell competition for the antigen-presenting cell as a model for immunodominance in the cytotoxic T lymphocyte response against minor histocompatibility antigens. Eur J Immunol (1999) 1.17
Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis (2011) 1.16
Immunodominance in the CTL response against minor histocompatibility antigens: interference between responding T cells, rather than with presentation of epitopes. J Immunol (1998) 1.15
Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit (1989) 1.13
Monoallelic expression of human PEG1/MEST is paralleled by parent-specific methylation in fetuses. Genomics (1997) 1.10
Host MHC class I gene control of NK-cell specificity in the mouse. Immunol Rev (1997) 1.10
Restoration of a tumorigenic phenotype by beta 2-microglobulin transfection to EL-4 mutant cells. J Exp Med (1992) 1.10
TAP1-deficient mice select a CD8+ T cell repertoire that displays both diversity and peptide specificity. Eur J Immunol (1996) 1.10
Beta2-microglobulin-deficient NK cells show increased sensitivity to MHC class I-mediated inhibition, but self tolerance does not depend upon target cell expression of H-2Kb and Db heavy chains. Eur J Immunol (1998) 1.09
Visualization of inhibitory Ly49 receptor specificity with soluble major histocompatibility complex class I tetramers. Eur J Immunol (2000) 1.09
Synergistic effect of IFN-gamma and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity. Eur J Immunol (2001) 1.09
Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur J Immunol (1994) 1.08
Review article: the clinical management of congenital chloride diarrhoea. Aliment Pharmacol Ther (2009) 1.07
Genetic Disorders of Membrane Transport III. Congenital chloride diarrhea. Am J Physiol (1999) 1.06
Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression. Opposing influences of T cell and natural killer mediated resistance? J Immunogenet (1987) 1.06
Clinical pharmacology of thalidomide. Eur J Clin Pharmacol (2001) 1.05
Afferent and efferent cellular interactions in natural resistance directed against MHC class I deficient tumor grafts. J Immunol (1988) 1.05
The expression of human natural killer cell receptors in early life. Scand J Immunol (2007) 1.04
Resistance to H-2-restricted but not to allo-H2-specific graft and cytotoxic T lymphocyte responses in lymphoma mutant. J Immunol (1990) 1.03
The congenital chloride diarrhea gene is expressed in seminal vesicle, sweat gland, inflammatory colon epithelium, and in some dysplastic colon cells. Histochem Cell Biol (2000) 1.03
Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc Natl Acad Sci U S A (1987) 1.03
NK cell receptor calibration: effects of MHC class I induction on killing by Ly49Ahigh and Ly49Alow NK cells. J Immunol (1997) 1.01
Different types of allospecific CTL clones identified by their ability to recognize peptide loading-defective target cells. Eur J Immunol (1991) 1.01
MHC class I recognition by NK receptors in the Ly49 family is strongly influenced by the beta 2-microglobulin subunit. J Immunol (2001) 1.01
Maternal and paternal chromosomes 7 show differential methylation of many genes in lymphoblast DNA. Genomics (2001) 1.01
Cytotoxic Thy 1,2-positive blasts with NK-like target selectivity in murine mixed lymphocyte cultures. J Immunol (1979) 1.01
A mutant cell in which association of class I heavy and light chains is induced by viral peptides. Cold Spring Harb Symp Quant Biol (1989) 1.01
Gastrointestinal complications after cardiac surgery. Br J Surg (2005) 1.00
Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol (2003) 0.99
H-2 allele-specific protection from NK cell lysis in vitro for lymphoblasts but not tumor targets. Protection mediated by alpha 1/alpha 2 domains. J Immunol (1994) 0.99
Innate and adaptive immunity to tumors: IL-12 is required for optimal responses. Eur J Immunol (2000) 0.99
Upregulation of CFTR expression but not SLC26A3 and SLC9A3 in ulcerative colitis. Am J Physiol Gastrointest Liver Physiol (2002) 0.98
Expression of SLC26A3, CFTR and NHE3 in the human male reproductive tract: role in male subfertility caused by congenital chloride diarrhoea. Mol Hum Reprod (2006) 0.98
Triggering of murine NK cells by CD40 and CD86 (B7-2). J Immunol (1999) 0.98
Interaction between isoniazid and theophylline. Eur J Respir Dis (1987) 0.97
Peptide dependency and selectivity of the NK cell inhibitory receptor Ly-49C. Eur J Immunol (1999) 0.97
Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man. J Pharm Pharmacol (1998) 0.96
Inhibition of human NK cell-mediated killing by CD1 molecules. J Immunol (2000) 0.96
T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J Immunol (2000) 0.96
Different modes of pathogenesis in T-cell-dependent autoimmunity: clues from two TCR transgenic systems. Immunol Rev (1999) 0.96
Further mutations in Brain 4 (POU3F4) clarify the phenotype in the X-linked deafness, DFN3. Hum Mol Genet (1995) 0.95
Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells. Eur J Immunol (1993) 0.95
Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther (1997) 0.94
Lung colonization and metastasis by disseminated B16 melanoma cells: H-2 associated control at the level of the host and the tumor cell. Int J Cancer (1985) 0.94
In vitro NK-activity and in vivo resistance to leukemia: studies of beige, beige//nude and wild-type hosts on C57BL background. Int J Cancer (1980) 0.93
High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol (2003) 0.93
IFN-gamma production and degranulation are differentially regulated in response to stimulation in murine natural killer cells. Scand J Immunol (2007) 0.92
NK cells in autoimmune disease. Curr Top Microbiol Immunol (2006) 0.92
Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells. Proc Natl Acad Sci U S A (1997) 0.91
Assessment of major histocompatibility complex class I interaction with Epstein-Barr virus and human immunodeficiency virus peptides by elevation of membrane H-2 and HLA in peptide loading-deficient cells. Eur J Immunol (1992) 0.91
Herpes simplex virus infection downmodulates NKG2D ligand expression. Scand J Immunol (2009) 0.91